Abstract
N-Substituted tetrazole was attempted to formylate which led to the formation of a novel triazene by opening of tetrazole ring via unusual Vilsmeir-Haack reaction. The formed product was proved by spectral analyses and X-Ray diffraction studies.
Keywords: Sydnone, triazole, terazole, formylation, iminium cation, Vilsmeir-Haack reaction.
Letters in Organic Chemistry
Title:Ring Opening of Tetrazole via Unusual Vilsmeir-Haack Reaction Forming Novel Triazenes
Volume: 12 Issue: 2
Author(s): Atukuri Dorababu, Ravindra R. Kamble, H. C. Devarajegowda and Gangadhar Y. Meti
Affiliation:
Keywords: Sydnone, triazole, terazole, formylation, iminium cation, Vilsmeir-Haack reaction.
Abstract: N-Substituted tetrazole was attempted to formylate which led to the formation of a novel triazene by opening of tetrazole ring via unusual Vilsmeir-Haack reaction. The formed product was proved by spectral analyses and X-Ray diffraction studies.
Export Options
About this article
Cite this article as:
Dorababu Atukuri, R. Kamble Ravindra, Devarajegowda H. C. and Y. Meti Gangadhar, Ring Opening of Tetrazole via Unusual Vilsmeir-Haack Reaction Forming Novel Triazenes, Letters in Organic Chemistry 2015; 12 (2) . https://dx.doi.org/10.2174/157017861202150213102528
DOI https://dx.doi.org/10.2174/157017861202150213102528 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Current Molecular Medicine Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Recent Advances in Epitope Design for Immunotherapy of Cancer
Recent Patents on Anti-Cancer Drug Discovery Brain Tumor-Related Epilepsy
Current Neuropharmacology Role of ABC Transporters in Veterinary Medicine: Pharmaco- Toxicological Implications
Current Medicinal Chemistry Immunoliposomes in Acute Myeloid Leukaemia Therapy: An Overview of Possible Targets and Obstacles
Current Medicinal Chemistry Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients
Current Pharmaceutical Design Mechanisms of Interferon Mediated Anti-Viral Resistance
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Receptor Tyrosine Kinases Take a Direct Route to Mitochondria: An Overview
Current Protein & Peptide Science Reduced-Intensity Transplantation in the Treatment of Haematological Malignancies: Current Status and Future-Prospects
Current Stem Cell Research & Therapy A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Monoclonal Antibodies in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Phosphoproteomics as a Promising Tool for Broadening the Analysis of Clinical Samples and for the Fight Against Cancer Disease
Current Pharmaceutical Analysis Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry Sources of β-Cells for Cell Therapy in Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry